SERVATRIX Biomed is a spin-off from the Autonomous University of Madrid (UAM) and the Spanish National Research Council (CSIC) dedicated to developing advanced treatments for fatty liver disease, particularly non-alcoholic steatohepatitis (NASH), and its progression to liver fibrosis and cirrhosis. Often referred to as the “silent pandemic of the 21st century,” fatty liver disease affects more than 25% of the global population. Despite its growing prevalence, there are currently no widely approved and effective drug treatments, therefore representing a huge medical need and a market opportunity.
Prototype/preclinical
2.600.000€
2029-2030
Biotechnology
17.46%
1.000€
Share this project on your website.
Copy and paste the following code into your content.
Non-alcoholic steatohepatitis (NASH), also known as Metabolic Associated Steatohepatitis (MASH), is a disease characterized by the accumulation of fat in the liver and its inflammation due to metabolic issues, not alcohol. As a result, the liver does not function properly, and over time, the disease can progress to fibrosis, cirrhosis, and liver failure. It has become a major health concern, with over 70 million global cases progressing to cirrhosis and responsible for more than 2 million deaths annually. It is now the leading cause of liver transplants in the US.
Despite the urgent need for treatments, drug development is still very inefficient to halt or reverse NASH/MASH progression. The problem is worsening as obesity and type 2 diabetes rates rise, fueling liver fat accumulation and inflammation. Nearly 20% of liver transplants in the US in 2024 were attributed to NASH, underscoring its severe medical and economic consequences.
Therefore, NASH is not only a medical issue but also an economic and social one. Due to the lack of successful pharmacological treatments, there is growing interest from the pharmaceutical industry, regulatory authorities, and researchers in facilitating the development of new therapies to reduce the severity of NASH. The NASH/MASH market is projected to grow from $3.5B in 2023 to $77.4B by 2031, with a CAGR of 47%, making it one of the most lucrative sectors in biotech. Altogether, SERVATRIX will take part in this huge market opportunity.
SERVATRIX Biomed is developing a novel therapy that targets a key mechanism involved in NASH progression: NRF2, a protein that regulates cellular defense against oxidative, inflammatory, and metabolic stress, three critical factors in chronic diseases like NASH.
Most current NRF2-targeting strategies cause an excessively strong activation of this protein. However, this approach has limitations, including off-target effects and poor specificity. SERVATRIX takes a different route, focusing on a lesser-known regulator of NRF2 discovered by our CSO. This unique strategy allows for moderate protein activation, balancing therapeutic benefits while minimizing risks.
The company has patented a new family of molecules that have already shown to completely block the disease progression in animal models with no adverse effects, therefore providing safety and therapeutic efficacy. This represents a differentiated and potentially game-changing approach to treating this disease.
SERVATRIX is built on over 15 years of research into NRF2 and its role in chronic diseases. The company is led by Dr. Antonio Cuadrado, a Professor of Biochemistry and Molecular Biology at the Autonomous University of Madrid, who is one of the world’s leading experts on NRF2. He has authored more than 200 scientific publications, including over 100 related to NRF2. He leads BenBedPhar (COST Action CA20121), a network of more than 400 researchers across 38 countries dedicated to the study of NRF2-based therapies.
SERVATRIX also brings together a highly experienced research team, collaborating with top-tier institutions such as the Autonomous University of Madrid, CSIC, and other European research centers. The management team includes professionals with strong backgrounds in pharmaceutical entrepreneurship and investment, supported by a Scientific Advisory Board composed of global experts in preclinical and clinical development.
SERVATRIX has gained significant recognition for its innovative approach:
With a clear Scientific Roadmap, strong expertise, and a differentiated therapeutic strategy, SERVATRIX is poised to transform the treatment landscape for NASH and other metabolic diseases.
NASH is now the leading cause of liver transplants, and its prevalence keeps rising due to poor diet and sedentary lifestyles, which in turn trigger obesity and type 2 diabetes. This toxic mix leads to fat accumulation in the liver, followed by inflammation, fibrosis, and eventually cirrhosis. As a result, NASH has become both a global health and economic priority, and a major focus for biotech innovation.
At Capital Cell, we see NASH as the Holy Grail of new drug development as it is one of the most valuable opportunities in biotech today. We have already invested in this space, and now we are adding Servatrix to our portfolio. But Servatrix has a key element that makes them stand out, its CSO, Antonio Cuadrado, a leading expert in NASH with over 160 high-impact publications and coordinator of BenBedPhar, a European research network of 400+ scientists across 38 countries. With such a leading expert at the helm, Servatrix brings a level of scientific credibility that few early-stage projects can offer.
From an investment perspective, the timing is ideal. Still in preclinical stage, Servatrix has already shown it can halt disease progression in NASH models, which positions the project greatly to start testing in humans. This, summed to its modest valuation of €2.6 million, can make early investors have a strong upside as the company moves toward clinical trials and potential pharma partnerships.
Servatrix brings together everything investors should be looking for: robust science, high-impact potential, a top-tier team, and access to a huge market—one that pharma giants like Novo Nordisk are already targeting with drugs like Ozempic.
The primary challenge of SERVATRIX will be to translate the promising preclinical results into successful human clinical trials. While the proprietary molecule has shown great potential in mouse models, there remains uncertainty about how it will perform in humans. Additionally, as the company works to secure regulatory approvals and navigate the complexities of clinical testing, it will need to ensure that the molecule’s efficacy and safety are demonstrated at the human level.
Already have an account? Please login here .